Conclusion
tumour
SOLID TUMOUR, TUMOUR
In this Phase 1/2 study, BGB-A333 alone or in combination with tislelizumab was generally well tolerated in patients with advanced solid tumours. The RP2D for BGB-A333 was estimated as 1350 mg Q3W. AEs reported with BGB-A333 were mostly mild to moderate in severity and consistent with those associated with other PD-L1 inhibitors. Preliminary anti-tumour activity was observed with BGB-A333 as both a single agent and in combination with tislelizumab. Co-administration of BGB-A333 with tislelizumab did not have a significant impact on the PK profile of either compound. Our findings in a small number of patients suggest that PD-1/PD-L1 combination therapy has the potential to augment the efficacy of PD-1 treatment with tislelizumab in selected tumour types; however, further investigation in larger-scale studies is warranted.